Literature DB >> 17287377

Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension.

John D Piette1, Michele Heisler, Dara Ganoczy, John F McCarthy, Marcia Valenstein.   

Abstract

OBJECTIVES: Global patient characteristics may affect adherence across all medications in a regimen, making medication-specific risk factors for adherence problems less important. Medication adherence was examined among patients with schizophrenia and comorbid physical conditions for consistency across therapeutic classes.
METHODS: A national sample of veterans was selected according to use of medication for schizophrenia, diabetes, and hypertension (N=1,686). Adherence to each medication type was assessed with medication possession ratios (MPRs). Multilevel logistic models were used to study the impact of medication type on adherence, as well as the effect of other medication characteristics (such as the average days of medication supplied per refill), health service use, and patients' sociodemographic characteristics.
RESULTS: Adherence was only modestly correlated across types of medication. Information about antipsychotic adherence explained only 13% and 16% of the variance in patients' antihypertensive and hypoglycemic MPRs, respectively. In unadjusted analyses, patients were more likely to have poorer adherence (MPR less than .8) to their antipsychotics (35%) than to their hypoglycemic (29%) or antihypertensive medications (26%) (p<.001). However, when analyses controlled for the average days' supply and other regimen characteristics, hypoglycemic and antihypertensive medications were associated with an increased risk of poor adherence relative to antipsychotics (both adjusted odds ratios=1.5, p<.001).
CONCLUSIONS: Patients with schizophrenia and comorbid physical conditions demonstrated important differences in adherence across medications in their regimen, reinforcing the importance of medication-specific factors in determining adherence behavior. The lower levels of adherence observed for antipsychotics may be associated with the shorter refill intervals for these medications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17287377     DOI: 10.1176/ps.2007.58.2.207

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  26 in total

1.  Association of Secondary Preventive Cardiovascular Treatment After Myocardial Infarction With Mortality Among Patients With Schizophrenia.

Authors:  Pirathiv Kugathasan; Henriette Thisted Horsdal; Jørgen Aagaard; Svend Eggert Jensen; Thomas Munk Laursen; René Ernst Nielsen
Journal:  JAMA Psychiatry       Date:  2018-12-01       Impact factor: 21.596

Review 2.  Management of schizophrenia in late life with antipsychotic medications: a qualitative review.

Authors:  Takefumi Suzuki; Gary Remington; Hiroyuki Uchida; Tarek K Rajji; Ariel Graff-Guerrero; David C Mamo
Journal:  Drugs Aging       Date:  2011-12-01       Impact factor: 3.923

3.  Is treatment adherence consistent across time, across different treatments and across diagnoses?

Authors:  Gregory E Simon; Do Peterson; Rebecca Hubbard
Journal:  Gen Hosp Psychiatry       Date:  2012-11-09       Impact factor: 3.238

4.  Emergency department utilization among Medicaid beneficiaries with schizophrenia and diabetes: the consequences of increasing medical complexity.

Authors:  Ruth S Shim; Benjamin G Druss; Shun Zhang; Giyeon Kim; Adesoji Oderinde; Sosunmolu Shoyinka; George Rust
Journal:  Schizophr Res       Date:  2013-12-28       Impact factor: 4.939

5.  Adherence to common cardiovascular medications in patients with schizophrenia vs. patients without psychiatric illness.

Authors:  Ashli Owen-Smith; Christine Stewart; Carla Green; Brian K Ahmedani; Beth E Waitzfelder; Rebecca Rossom; Laurel A Copeland; Gregory E Simon
Journal:  Gen Hosp Psychiatry       Date:  2015-07-30       Impact factor: 3.238

6.  Medication adherence among older adults with schizophrenia.

Authors:  Heather C Leutwyler; Patrick J Fox; Margaret Wallhagen
Journal:  J Gerontol Nurs       Date:  2013-01-18       Impact factor: 1.254

7.  The paradox of premature mortality in schizophrenia: new research questions.

Authors:  Hiram Joseph Wildgust; Richard Hodgson; Mike Beary
Journal:  J Psychopharmacol       Date:  2010-11       Impact factor: 4.153

Review 8.  Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?

Authors:  Hiram Joseph Wildgust; Mike Beary
Journal:  J Psychopharmacol       Date:  2010-11       Impact factor: 4.153

9.  Individual patients hold different beliefs to prescription medications to which they persist vs nonpersist and persist vs nonfulfill.

Authors:  Colleen A McHorney; Abhijit S Gadkari
Journal:  Patient Prefer Adherence       Date:  2010-07-21       Impact factor: 2.711

10.  Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER.

Authors:  Michael Birnbaum; Zafar Sharif
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.